Overview

Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
It is hypothesized that a strategy using prophylactic oral Tranexamic Acid (TXA) with therapeutic platelet transfusions is safe and effective compared to prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (who are at risk for bleeding).
Phase:
Phase 3
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Treatments:
Tranexamic Acid